Please enable Javascript
Video Insights
Roundtable: Focus on Bispecifics in Myeloma
Roundtable: Focus on Multiple Myeloma
Roundtable: Focus on Myelodysplastic Syndromes
Advertisement
Advertisement
Geoff Chong, MD, Shares Data on Novel Bispecific Antibody in Follicular Lymphoma
Geoff Chong, MD
Indolent B-Cell Lymphoma
|
April 26, 2024
The ELM-2 trial studied odronextamab in patients with relapsed or refractory follicular lymphoma.
View More
What are the Treatment Options for Patients With Lenalidomide-Refractory Myeloma?
Donna Catamero, ANP-BC, OCN, CCRC
Myeloma
|
April 24, 2024
Donna Catamero, ANP-BC, OCN, CCRC, discusses selinexor for myeloma, the BOSTON trial, and other recent advances in myeloma.
View More
Michel Zwaan, MD, PhD: 'Clear Medical Need’ in KMT2Ar Pediatric Acute Leukemias
Michel Zwaan, MD, PhD
Acute Lymphoblastic Leukemia
|
April 22, 2024
A phase II study presented at ASPHO 2024 evaluated revumenib in KMT2A-rearranged ALL and AML.
View More
Simona Colla, PhD, on Understanding the Molecular Mechanism of MDS
Simona Colla, PhD
Myelodysplastic Syndromes
|
April 19, 2024
Dr. Colla describes her current research at MD Anderson, such as developing new therapeutic approaches to MDS.
View More
Francesco Bertoni, MD, PhD, on Tumor Suppressor Activity in DLBCL
Francesco Bertoni, MD, PhD
Aggressive B-Cell Lymphoma
|
April 18, 2024
Dr. Bertoni and colleagues characterized two small nucleolar RNAs that exert tumor suppressor activity in DLBCL cells.
View More
CLL Expert Dr. Coombs on Clonal Hematopoiesis in Solid Tumors
Catherine Coombs, MD
Chronic Lymphocytic Leukemia
|
April 19, 2024
Catherine Coombs, MD, outlined some of her research into the solid tumor microenvironment, particularly in prostate cancer.
View More
Database Analysis Investigates T-Cell Malignancies After CAR-T
Magdi Elsallab, MD, PhD
Transplantation & Cellular Therapy
|
April 17, 2024
In approximately 12,000 reports of adverse events, the researchers found 19 cases of T-cell malignancies after CAR-T.
View More
Shyam Patel, MD, PhD, Explains the Patterns of Progression from CHIP to Myeloid Neoplasms
Melissa Badamo
Myelodysplastic Syndromes
|
April 16, 2024
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
View More
Kenneth Anderson, MD, on the ‘Revolution’ in Myeloma Therapies
Kenneth Anderson, MD
Myeloma
|
April 11, 2024
The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and ...
View More
Edward Cliff, MD, Shares Updated Analysis of Accelerated Approval Drugs in Oncology
Edward Cliff, MD
Blood Cancer Talks
|
April 11, 2024
Dr Cliff describes an analysis of oncology drugs that were approved via the FDA Accelerated Approval Program over 10 years.
View More
Shaikha AlQahtani, MD, on Cladribine in Pediatric Relapsed Leukemias
Shaikha Alqahtani, MD
Acute Myeloid Leukemia
|
April 10, 2024
Around 45% of patients had a complete response after cladribine, and 31% proceeded to transplant.
View More
Waitman Aumann, MD, MS, Shares Data on SIX1 Knockdown in T-ALL, AML
Melissa Badamo
Acute Myeloid Leukemia
|
April 9, 2024
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
View More
Claudio Cerchione, MD, PhD, Shares Promising Data on Emavusertib in AML
Leah Sherwood
Acute Myeloid Leukemia
|
April 16, 2024
Claudio Cerchione, MD, PhD, describes his presentation from AACR 2024 on a emavusertib triplet in patients with AML.
View More
Sundar Jagannath, MBBS, on Linvoseltamab in Relapsed or Refractory Myeloma
Melissa Badamo
Myeloma
|
April 8, 2024
The overall response rate was 71%, and the most common side effects were CRS, neutropenia, and anemia.
View More
Dr. Desai Discusses CMML Initiative With LLS
Leah Sherwood
Myelodysplastic Syndromes
|
March 25, 2024
The Leukemia and Lymphoma Society's CMML Initiative hopes for dedicated CMML trials and CMML-directed therapies.
View More
Dr. Siddiqi on Liso-Cel in the TRANSCEND CLL 004 Study
Tanya Siddiqi, MD
Chronic Lymphocytic Leukemia
|
March 29, 2024
Dr. Siddiqi shares data from the phase I/II TRANSCEND CLL 004 trial on liso-cel in patients with relapsed or refractory CLL.
View More
Dr. Osman on KRAS Mutations in CMML
Melissa Badamo
Myelodysplastic Syndromes
|
March 22, 2024
The case study included four patients with CMML who had KRAS mutations and a multitude of autoimmune diseases.
View More
Dr. Banerjee on Myeloma Awareness Month: Exciting Therapies, Global Disparities
Melissa Badamo
Myeloma
|
March 13, 2024
For Dr. Banerjee, this month is a call to action to mitigate global disparities in myeloma treatment.
View More
Drs. Kobold, Binder Discuss Novel Mutation-Specific CAR-T Cells as CLL Precision Therapy
Melissa Badamo
Chronic Lymphocytic Leukemia
|
March 11, 2024
The researchers developed CAR T-cells that target and eliminate mutated CLL cells while sparing healthy B-cells.
View More
What Is the Impact of GVHD on Myelofibrosis Relapse After HSCT?
Nicolaus Kröger, MD
Myelofibrosis
|
March 4, 2024
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
View More
Prithviraj Bose, MD, on the Importance of Rare Disease Day
Prithviraj Bose, MD
Myelofibrosis
|
February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
View More
How Do Patients Cope When Undergoing HSCT?
Richard Newcomb, MD
Transplantation & Cellular Therapy
|
February 26, 2024
Approach-oriented coping was associated with higher quality of life and lower symptoms of depression and anxiety.
View More
Dr. Richard Discusses FDA CAR-T Prescription Label Update Mandate
Shambavi Richard, MD
Transplantation & Cellular Therapy
|
February 20, 2024
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
View More
Pieter Sonneveld, MD, PhD, Talks PERSEUS Trial Results
Pieter Sonneveld, MD, PhD
Myeloma
|
February 16, 2024
The addition of daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy improved PFS.
View More
Justin Taylor, MD, on Overcoming BTK-Resistant Mutations in CLL
Justin Taylor, MD
Chronic Lymphocytic Leukemia
|
February 14, 2024
The study defined mutations that develop resistance to BTK inhibitors and evaluated the BTK degrader NX-2127 in CLL.
View More
Shambavi Richard, MD, Reflects on National Women Physicians Day
Shambavi Richard, MD
Video Insights
|
February 8, 2024
The scales are shifting in the STEM fields as more women step into positions of responsibility, leadership, and influence.
View More
Hematologist-in-Training Honored with ASH Abstract Achievement Award
Mariia Mikhaleva, MD
Video Insights
|
February 2, 2024
Mariia Mikhaleva MD, a research fellow at the Dana-Farber Cancer Institute, describes how it felt to receive the award.
View More
Mutational Burden in Patients with Treatment-Naïve CLL
Mariia Mikhaleva, MD
Chronic Lymphocytic Leukemia
|
January 26, 2024
The presence of two or more mutations are associated with high-risk cell features.
View More
Drs. Dahiya, Spiegel Explore Link Between CAR-T, Secondary Malignancies
Chadi Nabhan, MD, MBA, FACP
Transplantation & Cellular Therapy
|
January 26, 2024
The latest HemOnc Pulse episode looks at the science behind the statement from the FDA on the risk of CAR-T therapies.
View More
The Future of Bone Marrow Tissue Analysis in Hematologic Diseases
Sanjay Patel, MD
Video Insights
|
January 19, 2024
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
View More
View All Videos
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Subscribe Now
Knowledge Hubs
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Aggressive B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
Myeloma
MDS
MPN
Myelofibrosis
Transplantation & Cellular Therapy
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Aggressive B-Cell Lymphoma
Chronic Lymphocytic Leukemia
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACP
Editor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MD
Executive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Thomas Martin, MD
Associate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MD
Associate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPH
Associate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MD
Associate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MD
Associate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University